Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro

British Journal of Pharmacology

Volumn 171, Issue 18, 2014, Pages 4273-4288

  Knapman, Alisa ^a   Santiago, Marina ^a   Connor, Mark ^a  

^a MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT;

ANIMAL; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; HAMSTER; HUMAN; MEMBRANE POTENTIAL; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; CHO CELLS; CRICETINAE; CRICETULUS; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HUMANS; MEMBRANE POTENTIALS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 84906825514     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12785     Document Type: Article

References (57)

1. Abrol R, Kim SK, Bray JK, Trzaskowski B, Goddard WA 3rd, (2013). Conformational ensemble view of G protein-coupled receptors and the effect of mutations and ligand binding. Methods Enzymol 520: 31-48.
2. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The concise guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
3. Allouche S, Polastron J, Hasbi A, Homburger V, Jauzac P, (1999). Differential G-protein activation by alkaloid and peptide opioid agonists in the human neuroblastoma cell line SK-N-BE. Biochem J 342: 71-78.
4. Atwood BK, Lopez J, Wager-Miller J, Mackie K, Straiker A, (2011). Expression G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC Genomics 12: 14.
5. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL, (2001). A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276: 3130-3137.
6. 2B receptor polymorphisms. Mol Pharmacol 85: 127-138.
7. Beyer A, Koch T, Schroder H, Schulz S, Hollt V, (2004). Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization and resensitization of the human mu-opioid receptor. J Neurochem 89: 553-560.
8. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, et al. (1998). Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95: 9608-9613.
9. Bortsov AV, Millikan RC, Belfer I, Boortz-Marx RL, Arora H, McLean SA, (2012). μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 116: 896-902.
10. + channels (GIRKs). J Biol Chem 276: 11409-11413.
11. Cox B, (2013). Recent developments in the study of opioid receptors. Mol Pharmacol 83: 723-728.
12. Cox BM, Christie MJ, Devi L, Toll L, Traynor JR, (2014). Challenges for opioid receptor nomenclature. Brit J Pharmacol In Press.
13. Diatchenko L, Robinson JE, Maixner W, (2011). Elucidation of mu-opioid gene structure: how genetics can help predict therapeutic response to opioids. Eur J Pain Suppl 5: 433-448.
14. Galandrin S, Oligny-Longpre G, Bonin H, Ogawa K, Gales C, Bouvier M, (2008). Conformational rearrangements and signalling cascades involved in ligand-biased mitogen-activated protein kinase signalling through the β1-adrenergic receptor. Mol Pharmacol 74: 162-172.
15. Gerra G, Somaini L, Leonardi C, Cortese E, Maremmani I, Manfredini M, et al. (2014). Association between gene variants and response to buprenorphine maintenance treatment. Psychiatry Res 215: 202-207.
16. Gupta A, Decaillot FM, Gomes I, Tkalych O, Heimann AS, Ferro ES, et al. (2007). Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem 282: 5116-5124.
17. Gupta A, Rozenfeld R, Gomes I, Raehal KM, Decaillot FM, Bohn LM, et al. (2008). Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies. J Biol Chem 283: 10735-10744.
18. Herrick-Davis K, Grinde E, Cowan A, Mazurkiewicz JE, (2013). Fluorescence correlation spectroscopy analysis of serotonin, adrenergic, muscarinic, and dopamine receptor dimerization: the oligomer number puzzle. Mol Pharmacol 84: 630-642.
19. Huang P, Chen C, Mague SD, Blendy JA, Liu-Chen LY, (2012). A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability. Biochem J 441: 379-386.
20. Kenakin T, Miller LJ, (2010). Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265-304.
21. Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, et al. (2004). The 118 A > G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48: 1232-1239.
22. Klepstad P, Fladvad T, Skorpen F, Bjordal K, Caraceni A, Dale O, et al. (2011). Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 152: 1139-1145.
23. Knapman A, Connor M, (2014). Cellular signalling of non-synonymous single nucleotide polymorphisms of the human μ-Opioid Receptor (OPRM1). Br J Pharmacol doi: 10.1111/bph.12644; In Press.
24. Knapman A, Santiago M, Du YP, Bennallack PR, Christie MJ, Connor M, (2013). A continuous, fluorescence-based assay of μ-opioid receptor activation in AtT-20 cells. J Biomol Screen 18: 269-276.
25. Knapman A, Abogadie F, McIntyre P, Connor M, (2014). A real-time, fluorescence-based assay for measuring μ-opioid receptor modulation of adenylyl cyclase activity in Chinese hamster ovary cells. J Biomol Screen 19: 223-231.
26. Kroslak T, LaForge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ, (2007). The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 103: 77-87.
27. Law PY, Yung HW, Loh HH, (2000). Molecular mechanisms of opioid receptor signalling. Annu Rev Pharmacol Toxicol 40: 389-430.
28. V2.2 channels. Neurosci Lett 523: 190-194.
29. Lotsch J, Geisslinger G, (2005). Are μ-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 11: 82-89.
30. Luttrell LM, (2005). Composition and function of G protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity. J Mol Neurosci 26L: 253-264.
31. Mague SD, Blendy JA, (2010). OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend 108: 172-182.
32. Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA, (2009). Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci USA 106: 10847-10852.
33. 2+ channels in humanized mouse sensory neurons. Anesthesiology 115: 1054-1062.
34. Malik RU, Ritt M, DeVree BT, Neubig RR, Sunahara RK, Sivaramakrishnan S, (2013). Detection of G protein-selective G protein-coupled receptor (GPCR) conformations in live cells. J Biol Chem 288: 17167-17178.
35. Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, et al. (2012). Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature 485: 321-326.
36. 2+ channels by heterologously expressed wild-type and mutant human μ opioid receptors (hMORs) containing the A118G single-nucleotide polymorphism. J Neurophysiol 97: 1058-1067.
37. IR3 potassium channels and NMDA receptor conductance by l- and d- methadone in rat locus coeruleus. Br J Pharmacol 161: 1403-1413.
38. Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, et al. (2013). Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? J Pain Res 6: 331-353.
39. + currents in rat locus coeruleus neurons in vitro. Eur J Pharmacol 361: 157-163.
40. Oertel BG, Doehring A, Roskam B, Kettner M, Hackmann N, Ferreiros N, et al. (2012). Genetic-epigenetic interaction modulates μ-opioid receptor regulation. Hum Mol Genet 21: 4751-4760.
41. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ,; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
42. Pineyro G, Archer-Lahlou E, (2007). Ligand-specific receptor states: implications for opiate receptor signaling and regulation. Cell Signal 19: 8-19.
43. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, et al. (2011). A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 16: 809-817.
44. Ravindranathan A, Joslyn G, Robertson M, Schuckit MA, Whistler JL, White RL, (2009). Functional characterisation of human variants of the mu-opioid receptor gene. Proc Natl Acad Sci U S A 106: 10811-10816.
45. Reyes-Gibby CC, Shete S, Rakvag T, Bhat SV, Skorpen F, Bruera E, et al. (2007). Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130: 25-30.
46. Rivero G, Llorente J, McPherson J, Cooke A, Mundell SJ, McArdle CA, et al. (2012). Endomorphin-2: a biased agonist at the μ-opioid receptor. Mol Pharmacol 82: 178-188.
47. Sauer B, (1994). Site-specific recombination: developments and applications. Curr Opin Biotechnol 5: 521-527.
48. Singh VK, Bajpai K, Biswas S, Haq W, Khan MY, Mathur KB, (1997). Molecular biology of opioid receptors. Neuroimmunomodulation 4: 285-297.
49. Skorpen F, Laugsand EA, Klepdstad P, Kaasa S, (2008). Variable response to opioid treatment: any genetic predictors in sight? Palliat Med 22: 310-327.
50. Solak O, Erdogan MO, Yildiz H, Ulasli AM, Yaman F, Terzi ES, et al. (2014). Assessment of opioid receptor μ1 gene A118G polymorphism and its association with pain intensity in patients with fibromyalgia. Rheumatol Int doi: 10.1007/200296-014-2995-1; In Press.
51. Somogyi AA, Barrat DT, Coller JK, (2007). Pharmacogenetics of opioids. Clin Pharmacol Ther 81: 429-444.
52. Song Z, Du B, Wang K, Shi X, (2013). Effects of OPRM1 A118G polymorphism on epidural analgesia with fentanyl during labor: a meta-analysis. Genet Test Mol Biomarkers 17: 743-749.
53. Srinivasan S, Lubrano-Berthelier C, Govaerts C, Picard F, Santiago P, Conklin BR, et al. (2004). Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J Clin Invest 114: 1158-1164.
54. Virk MS, Arttamangkul S, Birdsong WT, Williams JT, (2009). Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci 29: 7341-7348.
55. Wachman EM, Hayes MJ, Brown MS, Paul J, Harvey-Wilkes K, Terrin N, et al. (2013). Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 309: 1821-1827.
56. Walter C, Lotsch J, (2009). Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 146: 270-275.
57. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W, (2005). Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280: 32618-32624.